New models towards assessing anti-cancer therapeutics.
Cancer is the subject of intense research around the world, but many questions about how the disease works remain unanswered. How exactly does cancer start and how do tumours grow? In fact, at present there are ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. However, many of the new anticancer agents are predicted to show clinical benefit in only small subpopulations of patients. The cancer stem cell model could explain not only how some cancers work but also why patients suffer relapses, providing a good opportunity to gain insight into the reasons why agents work or, more commonly, don't work, before going into a clinical trial.
Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/University of Salamanca, Salamanca, Spain.
Isabel
I
Romero-Camarero
Marcos
M
Barajas-Diego
Andrés
A
Castellanos-Martín
Ángel
Á
García-Martín
Gonzalo
G
Varela
Mar
M
Abad
María Dolores
MD
Ludeña
Jesús
J
Pérez-Losada
Isidro
I
Sánchez-García
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D016503:Drug Delivery Systems / Q000379:methods; D015195:Drug Design; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D012107:Research Design
D000970:Antineoplastic Agents